<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979390</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1316-I-103</org_study_id>
    <nct_id>NCT04979390</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of New Formulation SHR-1316 in Subjects With Advanced Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of the&#xD;
      new formulation SHR-1316 in subjects with advanced tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>SHR-1316 administrated intravenously (IV) at protocol defined dose levels</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence and severity of adverse events/serious adverse events (based on NCI-CTC AE 5.0)</measure>
    <time_frame>approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum concentration (Tmax)</measure>
    <time_frame>approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to time（AUC0-t）</measure>
    <time_frame>approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve extrapolated to infinity (AUC0-∞.)</measure>
    <time_frame>approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life (t1/2)</measure>
    <time_frame>approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (Vz)</measure>
    <time_frame>approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough concentration (Cmin)</measure>
    <time_frame>approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulatio of ratio (Rac)</measure>
    <time_frame>approximately 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of SHR-1316</measure>
    <time_frame>approximately 1 year</time_frame>
    <description>Anti-SHR-1316 antibody (ADA), neutralizing antibody (Nab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>approximately 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Tumor</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1316</intervention_name>
    <description>SHR-1316 administrated intravenously (IV) at protocol defined dose levels</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. Histologically or cytologically confirmed advanced cancer in patients who are fail to&#xD;
             current standard therapy or lack of effective therapy.&#xD;
&#xD;
          3. Estimated life expectancy ≥12 weeks.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          5. Adequate organ functions.&#xD;
&#xD;
          6. If of childbearing potential (male or female), agrees to practice an effective form of&#xD;
             contraception during study treatment and for at least 3 months following last&#xD;
             treatment dose.&#xD;
&#xD;
          7. Patients must be willing and able to provide written informed consent prior to the&#xD;
             performance of any study-specific procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of hypersensitivity to any components of the SHR-1316 product.&#xD;
&#xD;
          2. Patient- Prior treatment with the following agents:&#xD;
&#xD;
               1. &quot;Check-point inhibitors&quot;, including Programmed death receptor-1 (PD-1), PD-L1;&#xD;
&#xD;
               2. Receipt of investigational agents within 4 weeks prior to study treatment;&#xD;
&#xD;
               3. Current treatment on another therapeutic clinical trial, unless the observational&#xD;
                  (non-interventional) clinical trials or follow-up of interventional clinical&#xD;
                  trials;&#xD;
&#xD;
               4. Any anti-cancer therapy (including chemotherapy, immunotherapy, hormone therapy,&#xD;
                  target therapy, biotherapy or tumor embolization), administered within 4 weeks&#xD;
                  prior to study treatment; or within 6 weeks in the case of certain therapies&#xD;
                  (e.g., mitomycin C and nitrosoureas). Any such, unless discussed and explained&#xD;
                  with the sponsor;&#xD;
&#xD;
               5. Anticipated need for any anti-cancer therapy (including chemotherapy,&#xD;
                  immunotherapy, hormone therapy, or biotherapy) during SHR-1316 treatment; except&#xD;
                  palliative radiotherapy;&#xD;
&#xD;
               6. Receipt of any anti-cancer vaccines; receipt of immunomodulatory drugs within 4&#xD;
                  weeks prior to study treatment; topical, nasal spray and inhaled corticosteroids&#xD;
                  as well as systemic steroid therapy in physiological doses (such as: prednisone&#xD;
                  ≤10 mg/day) are acceptable.&#xD;
&#xD;
          3. Patients have unrecovered (ie, to NCI CTCAE grade ≤1) from all toxicity associated&#xD;
             with previous treatments (exception: patients may enter with continuing alopecia&#xD;
             irrespective of CTCAE grade; grade 2 peripheral nerve diseases).&#xD;
&#xD;
          4. Known Active central nervous system (CNS) metastases; Patients who had previously&#xD;
             received brain or meningeal metastasis therapy, who were clinically stable for at&#xD;
             least 8 weeks, and who had stopped systemic sex hormone therapy (such as： prednisone &gt;&#xD;
             10 mg/day) for more than 4 weeks were included.&#xD;
&#xD;
          5. Subjects with active autoimmune disease, history of autoimmune diseases, including but&#xD;
             not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus,&#xD;
             rheumatoid arthritis, inflammatory bowel disease, etc.&#xD;
&#xD;
          6. Active or history of immune deficiency, such as human immunodeficiency virus (HIV)&#xD;
             infection; History of organ transplantation.&#xD;
&#xD;
          7. History or evidence of cardiovascular (CV) risk including any of the following:&#xD;
             Congestive heart failure (Class &gt;2) as defined by the New York Heart Association&#xD;
             functional classification system (NYHA), unstable angina pectoris, Recent (within the&#xD;
             past 12 months) history of myocardial infarction, clinically significant&#xD;
             supraventricular or ventricular arrhythmias need treatment or intervention.&#xD;
&#xD;
          8. Patients with clinically significant ECG abnormalities (QT interval corrected for rate&#xD;
             by Fridericia's formula [QTcF] &gt;470 msec for female and &gt;450 msec for male on the ECG&#xD;
             obtained at Screening).&#xD;
&#xD;
          9. Active infection that need drug intervention or an unexplained fever &gt;38.5°C (fever&#xD;
             caused by cancer can be included according to the judgement of the researcher).&#xD;
&#xD;
         10. Active pulmonary tuberculosis infection.&#xD;
&#xD;
         11. Positive for Hepatitis B or C.&#xD;
&#xD;
         12. Known history of psychoactive drug abuse, alcohol abuse or drug use.&#xD;
&#xD;
         13. Known history of any other malignant cancer within past 3 years. Exceptions:&#xD;
             completely resected basal cell carcinoma and squamous cell carcinoma of the skin; and&#xD;
             completely resected carcinoma in situ of cervix.&#xD;
&#xD;
         14. Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or may&#xD;
             interfere with the interpretation of study results and, in the judgment of the&#xD;
             Investigator, would make the patient inappropriate for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuya Wang</last_name>
    <phone>13918749176</phone>
    <email>yuya.wang@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wen Jing</last_name>
    <phone>17721286191</phone>
    <email>wen.jing@hengrui.com</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

